Mitochondria as a target for neuroprotection: implications for Alzheimer´s disease

References

• Burte F, Carelli V, Chinnery PF, et al. Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol. 2015;11(1):11–24.
   PubMed Web of Science ®Google Scholar
• Corona JC, Duchen MR. Impaired mitochondrial homeostasis and neurodegeneration: towards new therapeutic targets? J Bioenerg Biomembr. 2015;47(1–2):89–99.
   PubMed Web of Science ®Google Scholar
• Wai T, Langer T. Mitochondrial dynamics and metabolic regulation. Trends Endocrinol Metab. 2016;27(2):105–117.
   PubMed Web of Science ®Google Scholar
• Karbowski M, Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol. 2012;123(2):157–171.
   PubMed Web of Science ®Google Scholar
• Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer’s disease. Science. 2004;304(5669):448–452.
   PubMed Web of Science ®Google Scholar
• Correia SC, Santos RX, Santos MS, et al. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer’s disease. Curr Alzheimer Res. 2013;10(4):406–419.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Santos MS, Oliveira CR, et al. Alzheimer’s disease and type 2 diabetes-related alterations in brain mitochondria, autophagy and synaptic markers. Biochim Biophys Acta. 2015;1852(8):1665–1675.
   PubMed Web of Science ®Google Scholar
• Cabezas-Opazo FA, Vergara-Pulgar K, Perez MJ, et al. Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev. 2015;2015:509654.
   PubMed Web of Science ®Google Scholar
• Morris JK, Honea RA, Vidoni ED, et al. Is Alzheimer’s disease a systemic disease? Biochim Biophys Acta. 2014;1842(9):1340–1349.
   PubMed Web of Science ®Google Scholar
• Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology. 2014;76 Pt A:27–50.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta. 2014;1842(8):1219–1231.
   PubMed Web of Science ®Google Scholar
• Perez-Pinzon MA, Stetler RA, Fiskum G. Novel mitochondrial targets for neuroprotection. J Cereb Blood Flow Metab. 2012;32(7):1362–1376.
   PubMed Web of Science ®Google Scholar
• Onyango IG, Dennis J, Khan SM. Mitochondrial dysfunction in Alzheimer’s disease and the rationale for bioenergetics based therapies. Aging Dis. 2016;7:201–214.
   PubMed Web of Science ®Google Scholar
• Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 2008;1147:395–412.
   PubMed Web of Science ®Google Scholar
• Luft R, Ikkos D, Palmieri G, et al. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest. 1962;41:1776–1804.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis. 2010;20(Suppl 2):S265–279.
   PubMed Web of Science ®Google Scholar
• Di Domenico F, Barone E, Perluigi M, et al. Strategy to reduce free radical species in Alzheimer’s disease: an update of selected antioxidants. Expert Rev Neurother. 2015;15(1):19–40.
   PubMed Web of Science ®Google Scholar
• Hampel H, Prvulovic D, Teipel S, et al. The future of Alzheimer’s disease: the next 10 years. Prog Neurobiol. 2011;95(4):718–728.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.
   PubMed Web of Science ®Google Scholar
• Correia SC, Santos RX, Perry G, et al. Mitochondrial importance in Alzheimer’s, Huntington’s and Parkinson’s diseases. Adv Exp Med Biol. 2012;724:205–221.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer’s disease. Antioxid Redox Signal. 2012;16(12):1434–1455.
   PubMed Web of Science ®Google Scholar
• Santos RX, Correia SC, Wang X, et al. Alzheimer’s disease: diverse aspects of mitochondrial malfunctioning. Int J Clin Exp Pathol. 2010;3(6):570–581.
   PubMed Web of Science ®Google Scholar
• Chen X, Stern D, Yan SD. Mitochondrial dysfunction and Alzheimer’s disease. Curr Alzheimer Res. 2006;3(5):515–520.
   PubMedGoogle Scholar
• Lunnon K, Ibrahim Z, Proitsi P, et al. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer’s disease blood. J Alzheimers Dis. 2012;30(3):685–710.
   PubMed Web of Science ®Google Scholar
• Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: implications for early intervention and therapeutics. Biochim Biophys Acta. 2011;1812(11):1359–1370.
   PubMed Web of Science ®Google Scholar
• Bubber P, Haroutunian V, Fisch G, et al. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol. 2005;57(5):695–703.
   PubMed Web of Science ®Google Scholar
• Azari NP, Pettigrew KD, Schapiro MB, et al. Early detection of Alzheimer’s disease: a statistical approach using positron emission tomographic data. J Cereb Blood Flow Metab. 1993;13(3):438–447.
   PubMed Web of Science ®Google Scholar
• Small GW, Komo S, La Rue A, et al. Early detection of Alzheimer’s disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci. 1996;802:70–78.
   PubMed Web of Science ®Google Scholar
• Eckert A, Schmitt K, Gotz J. Mitochondrial dysfunction - the beginning of the end in Alzheimer’s disease? Separate and synergistic modes of tau and amyloid-beta toxicity. Alzheimers Res Ther. 2011;3(2):15.
   PubMed Web of Science ®Google Scholar
• Gibson GE, Shi Q. A mitocentric view of Alzheimer’s disease suggests multi-faceted treatments. J Alzheimers Dis. 2010;20(Suppl 2):S591–607.
   PubMedGoogle Scholar
• Swerdlow RH, Khan SM. A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses. 2004;63(1):8–20.
   PubMed Web of Science ®Google Scholar
• Schon EA, Przedborski S. Mitochondria: the next (neurode)generation. Neuron. 2011;70(6):1033–1053.
   PubMed Web of Science ®Google Scholar
• Eckert A, Nisbet R, Grimm A, et al. March separate, strike together–role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta. 2014;1842(8):1258–1266.
   PubMed Web of Science ®Google Scholar
• Cadonic C, Sabbir MG, Albensi BC. Mechanisms of mitochondrial dysfunction in Alzheimer’s disease. Mol Neurobiol. 2015.doi:10.1007/s12035-015-9515-5. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Manczak M, Park BS, Jung Y, et al. Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromol Med. 2004;5(2):147–162.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer’s disease brain: new insights from redox proteomics. Eur J Pharmacol. 2006;545(1):39–50.
   PubMed Web of Science ®Google Scholar
• Aksenov MY, Tucker HM, Nair P, et al. The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer’s disease. Neurochem Res. 1999;24(6):767–774.
   PubMed Web of Science ®Google Scholar
• Tillement L, Lecanu L, Papadopoulos V. Alzheimer’s disease: effects of beta-amyloid on mitochondria. Mitochondrion. 2011;11(1):13–21.
   PubMed Web of Science ®Google Scholar
• Cottrell DA, Blakely EL, Johnson MA, et al. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology. 2001;57(2):260–264.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Kish SJ. Mitochondria in Alzheimer’s disease. Int. Rev. Neurobiol. 2002;53:341–385.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH. Brain aging, Alzheimer’s disease, and mitochondria. BBA. 2011;1812(12):1630–1639.
   PubMed Web of Science ®Google Scholar
• Yao J, Du H, Yan S, et al. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer’s disease. J Neurosci. 2011;31(6):2313–2320.
   PubMed Web of Science ®Google Scholar
• Hansson Petersen CA, Alikhani N, Wiehager B, et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. PNAS. 2008;105(35):13145–13150.
   PubMed Web of Science ®Google Scholar
• Sullivan PG, Brown MR. Mitochondrial aging and dysfunction in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(3):407–410.
   PubMed Web of Science ®Google Scholar
• Orrenius S. Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev. 2007;39(2–3):443–455.
   PubMed Web of Science ®Google Scholar
• Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60(8):759–767.
   PubMed Web of Science ®Google Scholar
• Silva DF, Esteves AR, Oliveira CR, et al. Mitochondria: the common upstream driver of amyloid-beta and tau pathology in Alzheimer’s disease. Curr Alzheimer Res. 2011;8(5):563–572.
   PubMed Web of Science ®Google Scholar
• Pratico D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59(6):972–976.
   PubMedGoogle Scholar
• Aluise CD, Robinson RA, Cai J, et al. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer’s disease: insights into memory loss in MCI. J Alzheimers Dis. 2011;23(2):257–269.
   PubMed Web of Science ®Google Scholar
• Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol. 2010;69(2):155–167.
   PubMed Web of Science ®Google Scholar
• Pratico D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001;21(12):4183–4187.
   PubMed Web of Science ®Google Scholar
• Manczak M, Jung Y, Park BS, et al. Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. J Neurochem. 2005;92(3):494–504.
   PubMed Web of Science ®Google Scholar
• Takuma K, Yao J, Huang J, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. Faseb J. 2005;19(6):597–598.
   PubMed Web of Science ®Google Scholar
• Curti D, Rognoni F, Gasparini L, et al. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer’s disease (AD) patients. Neurosci Let. 1997;236(1):13–16.
   PubMed Web of Science ®Google Scholar
• Gibson GE, Sheu KF, Blass JP, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol. 1988;45(8):836–840.
   PubMedGoogle Scholar
• Butterfield DA, Castegna A, Lauderback CM, et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol Aging. 2002;23(5):655–664.
   PubMed Web of Science ®Google Scholar
• Marcus DL, Thomas C, Rodriguez C, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease. Exp Neurol. 1998;150(1):40–44.
   PubMed Web of Science ®Google Scholar
• Leuner K, Schutt T, Kurz C, et al. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal. 2012;16(12):1421–1433.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Machado N, Mota PC, et al. Type 2 diabetic and Alzheimer’s disease mice present similar behavioral, cognitive, and vascular anomalies. J Alzheimers Dis. 2013;35(3):623–635.
   PubMed Web of Science ®Google Scholar
• Resende R, Moreira PI, Proenca T, et al. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med. 2008;44(12):2051–2057.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Cardoso S, Correia SC, et al. Metabolic alterations induced by sucrose intake and Alzheimer’s disease promote similar brain mitochondrial abnormalities. Diabetes. 2012;61(5):1234–1242.
   PubMed Web of Science ®Google Scholar
• Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2009;106(34):14670–14675.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang W, Li L, et al. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. BBA. 2014;1842(8):1240–1247.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang KZ, Chu CT. After the banquet: mitochondrial biogenesis, mitophagy, and cell survival. Autophagy. 2013;9(11):1663–1676.
   PubMed Web of Science ®Google Scholar
• Andreux PA, Houtkooper RH, Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov. 2013;12:465–483.
   PubMed Web of Science ®Google Scholar
• Onyango IG, Lu J, Rodova M, et al. Regulation of neuron mitochondrial biogenesis and relevance to brain health. BBA. 2010;1802(1):228–234.
   PubMed Web of Science ®Google Scholar
• Stotland A, Gottlieb RA. Mitochondrial quality control: easy come, easy go. BBA. 2015;1853(10 Pt B):2802–2811.
   PubMed Web of Science ®Google Scholar
• Correia SC, Resende R, Moreira PI, et al. Alzheimer’s disease-related misfolded proteins and dysfunctional organelles on autophagy menu. DNA Cell Biol. 2015;34(4):261–273.
   PubMed Web of Science ®Google Scholar
• Nixon RA, Yang DS, Lee JH. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy. 2008;4(5):590–599.
   PubMed Web of Science ®Google Scholar
• Cecconi F, Di Bartolomeo S, Nardacci R, et al. A novel role for autophagy in neurodevelopment. Autophagy. 2007;3(5):506–508.
   PubMed Web of Science ®Google Scholar
• Chen H, Chan DC. Mitochondrial dynamics–fusion, fission, movement, and mitophagy–in neurodegenerative diseases. Hum Mol Gen. 2009;18(R2):R169–R176.
   PubMed Web of Science ®Google Scholar
• Knott AB, Perkins G, Schwarzenbacher R, et al. Mitochondrial fragmentation in neurodegeneration. Nat Rev Neurosci. 2008;9(7):505–518.
   PubMed Web of Science ®Google Scholar
• Cai Q, Tammineni P. Alterations in mitochondrial quality control in Alzheimer’s disease. Front Cell Neurosci. 2016;10:24.
   PubMed Web of Science ®Google Scholar
• Cipolat S, Martins De Brito O, Dal Zilio B, et al. OPA1 requires mitofusin 1 to promote mitochondrial fusion. Proc Natl Acad Sci USA. 2004;101(45):15927–15932.
   PubMed Web of Science ®Google Scholar
• Bonda DJ, Wang X, Perry G, et al. Mitochondrial dynamics in Alzheimer’s disease: opportunities for future treatment strategies. Drugs Aging. 2010;27(3):181–192.
   PubMed Web of Science ®Google Scholar
• Twig G, Hyde B, Shirihai OS. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim Biophys Acta. 2008;1777(9):1092–1097.
   PubMed Web of Science ®Google Scholar
• Frank S, Gaume B, Bergmann-Leitner ES, et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell. 2001;1(4):515–525.
   PubMed Web of Science ®Google Scholar
• Frazier AE, Kiu C, Stojanovski D, et al. Mitochondrial morphology and distribution in mammalian cells. J Biol Chem. 2006;387(12):1551–1558.
   Web of Science ®Google Scholar
• Calkins MJ, Manczak M, Reddy PH. Mitochondria-targeted antioxidant SS31 prevents amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer’s disease. Pharmaceuticals. 2012;5(10):1103–1119.
   Google Scholar
• Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. J Cell Sci. 2005;118(Pt 23):5411–5419.
   PubMed Web of Science ®Google Scholar
• Koutsopoulos OS, Laine D, Osellame L, et al. Human Miltons associate with mitochondria and induce microtubule-dependent remodeling of mitochondrial networks. Biochim Biophys Acta. 2010;1803(5):564–574.
   PubMed Web of Science ®Google Scholar
• Saotome M, Safiulina D, Szabadkai G, et al. Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase. Proc Natl Acad Sci U S A. 2008;105(52):20728–20733.
   PubMed Web of Science ®Google Scholar
• Fransson S, Ruusala A, Aspenstrom P. The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking. Biochem Biophys Res Commun. 2006;344(2):500–510.
   PubMed Web of Science ®Google Scholar
• Labrousse AM, Zappaterra MD, Rube DA, et al. C. elegans dynamin-related protein DRP-1 controls severing of the mitochondrial outer membrane. Mol Cell. 1999;4(5):815–826.
   PubMed Web of Science ®Google Scholar
• Verstreken P, Ly CV, Venken KJ, et al. Synaptic mitochondria are critical for mobilization of reserve pool vesicles at Drosophila neuromuscular junctions. Neuron. 2005;47(3):365–378.
   PubMed Web of Science ®Google Scholar
• Varadi A, Johnson-Cadwell LI, Cirulli V, et al. Cytoplasmic dynein regulates the subcellular distribution of mitochondria by controlling the recruitment of the fission factor dynamin-related protein-1. J Cell Sci. 2004;117(Pt 19):4389–4400.
   PubMed Web of Science ®Google Scholar
• Misko A, Jiang S, Wegorzewska I, et al. Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci. 2010;30(12):4232–4240.
   PubMed Web of Science ®Google Scholar
• Saxton WM, Hollenbeck PJ. The axonal transport of mitochondria. J Cell Sci. 2012;125(Pt 9):2095–2104.
   PubMed Web of Science ®Google Scholar
• Rohas LM, St-Pierre J, Uldry M, et al. A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. Proc Natl Acad Sci U S A. 2007;104(19):7933–7938.
   PubMed Web of Science ®Google Scholar
• Qin W, Haroutunian V, Katsel P, et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol. 2009;66(3):352–361.
   PubMedGoogle Scholar
• Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem. 2012;120(3):419–429.
   PubMed Web of Science ®Google Scholar
• Calkins M, Mao P, Calkins MJ, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J Alzheimers Dis. 2010;20(Suppl 2):S609–S631.
   Google Scholar
• Zhang W, Gu GJ, Shen X, et al. Neural stem cell transplantation enhances mitochondrial biogenesis in a transgenic mouse model of Alzheimer’s disease-like pathology. Neurobiol Aging. 2015;36(3):1282–1292.
   PubMed Web of Science ®Google Scholar
• Xu S, Zhong M, Zhang L, et al. Overexpression of Tfam protects mitochondria against beta-amyloid-induced oxidative damage in SH-SY5Y cells. Febs J. 2009;276(14):3800–3809.
   PubMed Web of Science ®Google Scholar
• Katsouri L, Parr C, Bogdanovic N, et al. PPARgamma co-activator-1alpha (PGC-1alpha) reduces amyloid-beta generation through a PPARgamma-dependent mechanism. J Alzheimers Dis. 2011;25(1):151–162.
   PubMed Web of Science ®Google Scholar
• Dumont M, Stack C, Elipenahli C, et al. PGC-1alpha overexpression exacerbates beta-amyloid and tau deposition in a transgenic mouse model of Alzheimer’s disease. Faseb J. 2014;28(4):1745–1755.
   PubMed Web of Science ®Google Scholar
• Santos RX, Correia SC, Carvalho C, et al. Mitophagy in neurodegeneration: an opportunity for therapy? Curr Drug Targets. 2011;12(6):790–799.
   PubMed Web of Science ®Google Scholar
• Wong E, Cuervo AM. Autophagy gone awry in neurodegenerative diseases. Nature Neurosci. 2010;13(7):805–811.
   PubMed Web of Science ®Google Scholar
• Nixon RA, Yang DS. Autophagy failure in Alzheimer’s disease–locating the primary defect. Neurobiol Dis. 2011;43(1):38–45.
   PubMed Web of Science ®Google Scholar
• Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer’s disease. J Neurosci. 2001;21(9):3017–3023.
   PubMed Web of Science ®Google Scholar
• Moreira PI, Siedlak SL, Wang X, et al. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol. 2007;66(6):525–532.
   PubMed Web of Science ®Google Scholar
• Nixon RA, Wegiel J, Kumar A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64(2):113–122.
   PubMed Web of Science ®Google Scholar
• Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120(Pt 23):4081–4091.
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC, DiFiglia M, Heintz N, et al. Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy. 2005;1(1):11–22.
   PubMed Web of Science ®Google Scholar
• Kamat PK, Kalani A, Kyles P, et al. Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease. Cell Biochem Biophys. 2014;70(2):707–719.
   PubMed Web of Science ®Google Scholar
• Shaerzadeh F, Motamedi F, Khodagholi F. Inhibition of akt phosphorylation diminishes mitochondrial biogenesis regulators, tricarboxylic acid cycle activity and exacerbates recognition memory deficit in rat model of Alzheimer’s disease. Cell Mol Neurobiol. 2014;34(8):1223–1233.
   PubMed Web of Science ®Google Scholar
• Hung SY, Huang WP, Liou HC, et al. Autophagy protects neuron from Abeta-induced cytotoxicity. Autophagy. 2009;5(4):502–510.
   PubMed Web of Science ®Google Scholar
• Cataldo AM, Barnett JL, Berman SA, et al. Gene expression and cellular content of cathepsin D in Alzheimer’s disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron. 1995;14(3):671–680.
   PubMed Web of Science ®Google Scholar
• Moreira PI, Santos RX, Zhu X, et al. Autophagy in Alzheimer’s disease. Expert Rev Neurother. 2010;10(7):1209–1218.
   PubMed Web of Science ®Google Scholar
• Corrado M, Scorrano L, Campello S. Mitochondrial dynamics in cancer and neurodegenerative and neuroinflammatory diseases. Int J Biochem Cell Biol. 2012;2012:729290.
   PubMedGoogle Scholar
• Wang X, Su B, Zheng L, et al. The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. J Neurochem. 2009;109(Suppl 1):153–159.
   PubMed Web of Science ®Google Scholar
• Wang X, Su B, Siedlak SL, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A. 2008;105(49):19318–19323.
   PubMed Web of Science ®Google Scholar
• Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: implications for neuronal damage. Hum Mol Gen. 2011;20(13):2495–2509.
   PubMed Web of Science ®Google Scholar
• Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci. 2009;29(28):9090–9103.
   PubMed Web of Science ®Google Scholar
• Chan DC. Dissecting mitochondrial fusion. Dev Cell. 2006;11(5):592–594.
   PubMed Web of Science ®Google Scholar
• Taguchi N, Ishihara N, Jofuku A, et al. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem. 2007;282(15):11521–11529.
   PubMed Web of Science ®Google Scholar
• Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science. 2009;324(5923):102–105.
   PubMed Web of Science ®Google Scholar
• DuBoff B, Feany M, Gotz J. Why size matters - balancing mitochondrial dynamics in Alzheimer’s disease. Trends Neurosci. 2013;36(6):325–335.
   PubMed Web of Science ®Google Scholar
• Wang X, Su B, Fujioka H, et al. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. Am J Pathol. 2008;173(2):470–482.
   PubMed Web of Science ®Google Scholar
• Silva DF, Selfridge JE, Lu J, et al. Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum Mol Gen. 2013;22(19):3931–3946.
   PubMed Web of Science ®Google Scholar
• Gan X, Huang S, Wu L, et al. Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer’s disease cybrid cell. Bba. 2014;1842(2):220–231.
   PubMed Web of Science ®Google Scholar
• Wang MJ, Manczak M, Mao P, et al. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum Mol Gen. 2011;20(23):4515–4529.
   PubMed Web of Science ®Google Scholar
• Park J, Choi H, Min JS, et al. Loss of mitofusin 2 links beta-amyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress in neuron cells. J Neurochem. 2015;132(6):687–702.
   PubMed Web of Science ®Google Scholar
• Reddy PH, Tripathi R, Troung Q, et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta. 2012;1822(5):639–649.
   PubMed Web of Science ®Google Scholar
• Cogliati S, Frezza C, Soriano ME, et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell. 2013;155(1):160–171.
   PubMed Web of Science ®Google Scholar
• Rabinovici GD, Furst AJ, Alkalay A, et al. Increased metabolic vulnerability in early-onset Alzheimer’s disease is not related to amyloid burden. Brain. 2010;133(Pt 2):512–528.
   PubMed Web of Science ®Google Scholar
• Youle RJ, Van Der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337(6098):1062–1065.
   PubMed Web of Science ®Google Scholar
• Zhang L, Trushin S, Christensen TA, et al. Altered brain energetics induces mitochondrial fission arrest in Alzheimer’s disease. Sci Rep. 2016;6:18725.
   PubMed Web of Science ®Google Scholar
• Selfridge JE, Lezi E, Lu J, et al. Role of mitochondrial homeostasis and dynamics in Alzheimer’s disease. Neurobiol Dis. 2013;51:3–12.
   PubMed Web of Science ®Google Scholar
• Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008;60(5):748–766.
   PubMed Web of Science ®Google Scholar
• Terwel D, Dewachter I, Van Leuven F. Axonal transport, tau protein, and neurodegeneration in Alzheimer’s disease. NeuroMolecular Med. 2002;2(2):151–165.
   PubMed Web of Science ®Google Scholar
• Stokin GB, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science. 2005;307(5713):1282–1288.
   PubMed Web of Science ®Google Scholar
• Dai J, Buijs RM, Kamphorst W, et al. Impaired axonal transport of cortical neurons in Alzheimer’s disease is associated with neuropathological changes. Brain Res. 2002;948(1–2):138–144.
   PubMed Web of Science ®Google Scholar
• Trimmer PA, Borland MK. Differentiated Alzheimer’s disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxid Redox Signal. 2005;7(9–10):1101–1109.
   PubMed Web of Science ®Google Scholar
• Pigino G, Morfini G, Pelsman A, et al. Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci. 2003;23(11):4499–4508.
   PubMed Web of Science ®Google Scholar
• Massaad CA, Amin SK, Hu L, et al. Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer’s disease. Plos One. 2010;5(5):e10561.
   PubMed Web of Science ®Google Scholar
• Calkins MJ, Reddy PH. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer’s disease neurons. Biochim Biophys Acta. 2011;1812(4):507–513.
   PubMed Web of Science ®Google Scholar
• Lazarov O, Morfini GA, Pigino G, et al. Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer’s disease-linked mutant presenilin 1. J Neurosci. 2007;27(26):7011–7020.
   PubMed Web of Science ®Google Scholar
• Rui Y, Tiwari P, Xie Z, et al. Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. J Neurosci. 2006;26(41):10480–10487.
   PubMed Web of Science ®Google Scholar
• Pigino G, Morfini G, Atagi Y, et al. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci U S A. 2009;106(14):5907–5912.
   PubMed Web of Science ®Google Scholar
• Zhao XL, Wang WA, Tan JX, et al. Expression of beta-amyloid induced age-dependent presynaptic and axonal changes in Drosophila. J Neurosci. 2010;30(4):1512–1522.
   PubMed Web of Science ®Google Scholar
• Du H, Guo L, Yan S, et al. Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc Natl Acad Sci U S A. 2010;107(43):18670–18675.
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329–344.
   PubMed Web of Science ®Google Scholar
• Hampel H, Schneider LS, Giacobini E, et al. Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015;15(1):83–105.
   PubMed Web of Science ®Google Scholar
• Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer’s disease. Annu Rev Med. 2006;57:513–533.
   PubMed Web of Science ®Google Scholar
• Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ. 2011;155(3):219–229.
   PubMed Web of Science ®Google Scholar
• Awasthi M, Singh S, Pandey VP, et al. Alzheimer’s disease: an overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products. J Neurol Sci. 2016;361:256–271.
   PubMed Web of Science ®Google Scholar
• Muller WE, Eckert A, Kurz C, et al. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer’s disease–therapeutic aspects. Mol Neurobiol. 2010;41(2–3):159–171.
   PubMed Web of Science ®Google Scholar
• Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol. 2007;47:629–656.
   Google Scholar
• Ruszkiewicz J, Albrecht J. Changes in the mitochondrial antioxidant systems in neurodegenerative diseases and acute brain disorders. Neurochem Int. 2015;88:66–72.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh A. A review on mitochondrial restorative mechanism of antioxidants in Alzheimer’s disease and other neurological conditions. Front Pharmacol. 2015;6:206.
   PubMed Web of Science ®Google Scholar
• Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta. 2012;1822(5):631–638.
   PubMed Web of Science ®Google Scholar
• Murphy MP, Smith RA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev. 2000;41(2):235–250.
   PubMed Web of Science ®Google Scholar
• Wongrakpanich A, Geary SM, Joiner ML, et al. Mitochondria-targeting particles. Nanomedicine. 2014;9(16):2531–2543.
   PubMed Web of Science ®Google Scholar
• Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96–103.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Cuenca S, Cocheme HM, Logan A, et al. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med. 2010;48(1):161–172.
   PubMed Web of Science ®Google Scholar
• Miquel E, Cassina A, Martinez-Palma L, et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med. 2014;70:204–213.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Chandran K, Kalivendi SV, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson’s disease model. Free Radic Biol Med. 2010;49(11):1674–1684.
   PubMed Web of Science ®Google Scholar
• Kelso GF, Porteous CM, Coulter CV, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 2001;276(7):4588–4596.
   PubMed Web of Science ®Google Scholar
• McManus MJ, Murphy MP, Franklin JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci. 2011;31(44):15703–15715.
   PubMed Web of Science ®Google Scholar
• Ng LF, Gruber J, Cheah IK, et al. The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease. Free Radic Biol Med. 2014;71:390–401.
   PubMed Web of Science ®Google Scholar
• Snow BJ, Rolfe FL, Lockhart MM, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disorders. 2010;25(11):1670–1674.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Weilert F, Orr DW, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30(7):1019–1026.
   PubMed Web of Science ®Google Scholar
• Carvalho C, Katz PS, Dutta S, et al. Increased susceptibility to amyloid-beta toxicity in rat brain microvascular endothelial cells under hyperglycemic conditions. J Alzheimers Dis. 2014;38(1):75–83.
   PubMed Web of Science ®Google Scholar
• Lu L, Guo L, Gauba E, et al. Transient cerebral ischemia promotes brain mitochondrial dysfunction and exacerbates cognitive impairments in young 5xFAD mice. Plos One. 2015;10(12):e0144068.
   Google Scholar
• Obulesu M, Jhansilakshmi M. Neuroprotective role of nanoparticles against Alzheimer’s disease. Curr Drug Metab. 2016;17(2):142–149.
   PubMed Web of Science ®Google Scholar
• Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A. 2012;109(40):16288–16293.
   PubMed Web of Science ®Google Scholar
• Szeto HH. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann N Y Acad Sci. 2008;1147:112–121.
   PubMed Web of Science ®Google Scholar
• Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682–34690.
   PubMed Web of Science ®Google Scholar
• Lai AY, McLaurin J. Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease. Biochim Biophys Acta. 2012;1822(10):1629–1637.
   PubMed Web of Science ®Google Scholar
• Steele JW, Gandy S. Latrepirdine (Dimebon(R)), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy. 2013;9(4):617–618.
   PubMed Web of Science ®Google Scholar
• Yang DS, Stavrides P, Mohan PS, et al. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy. 2011;7(7):788–789.
   PubMed Web of Science ®Google Scholar
• Majumder S, Richardson A, Strong R, et al. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. Plos One. 2011;6(9):e25416.
   PubMed Web of Science ®Google Scholar
• Ozcelik S, Fraser G, Castets P, et al. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. Plos One. 2013;8(5):e62459.
   PubMed Web of Science ®Google Scholar
• Vingtdeux V, Chandakkar P, Zhao H, et al. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation. Faseb J. 2011;25(1):219–231.
   PubMed Web of Science ®Google Scholar
• Hensley K, Gabbita SP, Venkova K, et al. A derivative of the brain metabolite lanthionine ketimine improves cognition and diminishes pathology in the 3 x Tg-AD mouse model of Alzheimer disease. J Neuropathol Exp Neurol. 2013;72(10):955–969.
   PubMed Web of Science ®Google Scholar
• Hensley K, Harris-White ME. Redox regulation of autophagy in healthy brain and neurodegeneration. Neurobiol Dis. 2015;84:50–59.
   PubMed Web of Science ®Google Scholar
• Congdon EE, Wu JW, Myeku N, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy. 2012;8(4):609–622.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996;93(20):11213–11218.
   PubMed Web of Science ®Google Scholar
• Necula M, Breydo L, Milton S, et al. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry. 2007;46(30):8850–8860.
   PubMed Web of Science ®Google Scholar
• Medina DX, Caccamo A, Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011;21(2):140–149.
   PubMed Web of Science ®Google Scholar
• Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. Faseb J. 2008;22(3):703–712.
   PubMed Web of Science ®Google Scholar
• Atamna H. Amino acids variations in amyloid-beta peptides, mitochondrial dysfunction, and new therapies for Alzheimer’s disease. J Bioenerg Biomembr. 2009;41(5):457–464.
   PubMed Web of Science ®Google Scholar
• Atamna H, Kumar R. Protective role of methylene blue in Alzheimer’s disease via mitochondria and cytochrome c oxidase. J Alzheimers Dis. 2010;20(Suppl 2):S439–S452.
   Google Scholar
• Wen Y, Li W, Poteet EC, et al. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem. 2011;286(18):16504–16515.
   PubMed Web of Science ®Google Scholar
• Atamna H, Atamna W, Al-Eyd G, et al. Combined activation of the energy and cellular-defense pathways may explain the potent anti-senescence activity of methylene blue. Redox Biol. 2015;6:426–435.
   PubMed Web of Science ®Google Scholar
• Cheng A, Hou Y, Mattson MP. Mitochondria and neuroplasticity. ASN Neuro. 2010;2(5):e00045.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang PJ, Sha HY, et al. Neural stem cell transplants improve cognitive function without altering amyloid pathology in an APP/PS1 double transgenic model of Alzheimer’s disease. Mol Neurobiol. 2014;50(2):423–437.
   PubMed Web of Science ®Google Scholar
• Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009;106(32):13594–13599.
   PubMed Web of Science ®Google Scholar
• Qi X, Qvit N, Su YC, et al. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci. 2013;126(Pt 3):789–802.
   PubMed Web of Science ®Google Scholar
• Su YC, Qi X. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation. Hum Mol Gen. 2013;22(22):4545–4561.
   PubMed Web of Science ®Google Scholar
• Guo X, Disatnik MH, Monbureau M, et al. Inhibition of mitochondrial fragmentation diminishes Huntington’s disease-associated neurodegeneration. J Clin Invest. 2013;123(12):5371–5388.
   PubMed Web of Science ®Google Scholar
• Reddy PH, Reddy TP, Manczak M, et al. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Res Rev. 2011;67(1–2):103–118.
   PubMed Web of Science ®Google Scholar
• Cassidy-Stone A, Chipuk JE, Ingerman E, et al. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008;14(2):193–204.
   PubMed Web of Science ®Google Scholar
• Xie N, Wang C, Lian Y, et al. Inhibition of mitochondrial fission attenuates Abeta-induced microglia apoptosis. Neuroscience. 2014;256:36–42.
   PubMed Web of Science ®Google Scholar
• Reddy PH. Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer’s disease? Biochim Biophys Acta. 2013;1832(1):67–75.
   PubMed Web of Science ®Google Scholar
• Manczak M, Sheiko T, Craigen WJ, et al. Reduced VDAC1 protects against Alzheimer’s disease, mitochondria, and synaptic deficiencies. J Alzheimers Dis. 2013;37(4):679–690.
   PubMed Web of Science ®Google Scholar
• Folch J, Petrov D, Ettcheto M, et al. Masitinib for the treatment of mild to moderate Alzheimer’s disease. Expert Rev Neurother. 2015;15(6):587–596.
   PubMed Web of Science ®Google Scholar
• Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther. 2012;342(3):619–630.
   PubMed Web of Science ®Google Scholar